Cargando…

Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats

BACKGROUND: Recent clinical studies have shown that treatment with LCZ696, a complex containing the angiotensin receptor blocker valsartan and neprilysin inhibitor sacubitril, improves the prognosis of heart failure patients with a reduced ejection fraction. This study evaluated whether LCZ696 affec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miyoshi, Toru, Nakamura, Kazufumi, Miura, Daiji, Yoshida, Masashi, Saito, Yukihiro, Akagi, Satoshi, Ohno, Yuko, Kondo, Megumi, Ito, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Via Medica 2019
Materias:	Basic Science and Experimental Cardiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084392/ https://www.ncbi.nlm.nih.gov/pubmed/29718530 http://dx.doi.org/10.5603/CJ.a2018.0048

Ejemplares similares

Safety of the neprilysin/renin-angiotensin system inhibitor LCZ696
por: Li, Bo, et al.
Publicado: (2017)

LCZ696 ameliorates doxorubicin-induced cardiomyocyte toxicity in rats
por: Miyoshi, Toru, et al.
Publicado: (2022)

LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure and hypertension
por: Lefkowitz, Martin P
Publicado: (2011)

LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure
por: Lefkowitz, Martin P
Publicado: (2015)

LCZ696, an Angiotensin Receptor-Neprilysin Inhibitor, Improves Cardiac Hypertrophy and Fibrosis and Cardiac Lymphatic Remodeling in Transverse Aortic Constriction Model Mice
por: Ge, Qing, et al.
Publicado: (2020)

The angiotensin receptor and neprilysin inhibitor, LCZ696, in heart failure: A meta-analysis of randomized controlled trials
por: Chen, Yan, et al.
Publicado: (2022)

Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction
por: Ito, Sadayoshi, et al.
Publicado: (2015)

Angiotensin II receptor Neprilysin inhibitor (LCZ696) compared to Valsartan attenuates Hepatotoxicity in STZ-induced hyperglycemic rats
por: Alqahtani, Faleh, et al.
Publicado: (2020)

Prevention against renal damage in rats with subtotal nephrectomy by sacubitril/valsartan (LCZ696), a dual‐acting angiotensin receptor‐neprilysin inhibitor
por: Ushijima, Kentaro, et al.
Publicado: (2017)

LCZ696 Ameliorates Isoproterenol-Induced Acute Heart Failure in Rats by Activating the Nrf2 Signaling Pathway
por: Hou, Min, et al.
Publicado: (2022)

LCZ696 ameliorates lipopolysaccharide-induced endothelial injury
por: Gao, Aihong, et al.
Publicado: (2021)

The angiotensin receptor neprilysin inhibitor LCZ696 attenuates renal fibrosis via ASK1/JNK/p38 MAPK-mediated apoptosis in unilateral ureteral obstruction
por: Ding, Jun, et al.
Publicado: (2023)

A Meta-Analysis on the Effect and Safety of LCZ696 in the Treatment of Hypertension
por: Zheng, Li, et al.
Publicado: (2021)

Cardioprotective Effects of LCZ696 (Sacubitril/Valsartan) After Experimental Acute Myocardial Infarction
por: Ishii, Masanobu, et al.
Publicado: (2017)

A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure
por: McMurray, John, et al.
Publicado: (2015)

PARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure?
por: Kaplinsky, Edgardo
Publicado: (2015)

The effect of LCZ696 (sacubitril/valsartan) on amyloid‐β concentrations in cerebrospinal fluid in healthy subjects
por: Langenickel, Thomas H., et al.
Publicado: (2016)

Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF
por: Jhund, Pardeep S., et al.
Publicado: (2015)

Effect and safety of LCZ696 in the treatment of hypertension: A meta-analysis of 9 RCT studies
por: Li, Qiongqiong, et al.
Publicado: (2019)

Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization
por: Langenickel, Thomas H., et al.
Publicado: (2016)

The protective effect of LCZ696 in coxsackievirus B3‐induced acute viral myocarditis mice
por: Jing, Xu, et al.
Publicado: (2022)

Efficacy of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors in the Treatment of Chronic Heart Failure: A Review of Landmark Trials
por: Bratsos, Sosipatros
Publicado: (2019)

Heart Failure Treatments Such As Angiotensin Receptor/Neprilysin Inhibitor Improve Heart Failure Status and Glucose Metabolism
por: Kashiwagi, Yusuke, et al.
Publicado: (2022)

Angiotensin II receptor blocker LCZ696 attenuates cardiac remodeling through the inhibition of the ERK signaling pathway in mice with pregnancy-associated cardiomyopathy
por: Wang, Yi, et al.
Publicado: (2019)

Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction
por: Kobalava, Zhanna, et al.
Publicado: (2016)

Correction to: Angiotensin II receptor blocker LCZ696 attenuates cardiac remodeling through the inhibition of the ERK signaling pathway in mice with pregnancy‑associated cardiomyopathy
por: Wang, Yi, et al.
Publicado: (2020)

Efficacy of shear wave elasticity for evaluating myocardial hypertrophy in hypertensive rats
por: Takaya, Yoichi, et al.
Publicado: (2021)

LCZ696, a promising novel agent in treating hypertension (a meta-analysis of randomized controlled trials)
por: Ye, Liwen, et al.
Publicado: (2017)

Comparison of Efficacy and Safety of Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis
por: Haseeb, Muhammad Talha, et al.
Publicado: (2023)

Effects of Angiotensin Receptor-Neprilysin Inhibitors Versus Enalapril or Valsartan on Patients With Heart Failure: A Systematic Review and Meta-Analysis
por: Jain, Arpit, et al.
Publicado: (2023)

Evaluation of Pharmacokinetic and Pharmacodynamic Drug–Drug Interaction of Sacubitril/Valsartan (LCZ696) and Sildenafil in Patients With Mild‐to‐Moderate Hypertension
por: Hsiao, H‐L, et al.
Publicado: (2017)

LCZ696 Therapy Reduces Ventricular Tachyarrhythmia Inducibility in a Myocardial Infarction-Induced Heart Failure Rat Model
por: Chang, Po-Cheng, et al.
Publicado: (2019)

LCZ696 Attenuated Doxorubicin-Induced Chronic Cardiomyopathy Through the TLR2-MyD88 Complex Formation
por: Ye, Shiju, et al.
Publicado: (2021)

The Antihypertensive Effects and Safety of LCZ696 in Patients with Hypertension: A Systemic Review and Meta-Analysis of Randomized Controlled Trials
por: Chua, Su-Kiat, et al.
Publicado: (2021)

Direct actions of dapagliflozin and interactions with LCZ696 and spironolactone on cardiac fibroblasts of patients with heart failure and reduced ejection fraction
por: Ortega‐Paz, Luis, et al.
Publicado: (2022)

Pemafibrate Prevents Rupture of Angiotensin II-Induced Abdominal Aortic Aneurysms
por: Amioka, Naofumi, et al.
Publicado: (2022)

Sacubitril/valsartan (LCZ696) ameliorates hyperthyroid-induced cardiac hypertrophy in male rats through modulation of miR-377, let-7 b, autophagy, and fibrotic signaling pathways
por: Khamis, Tarek, et al.
Publicado: (2022)

Effect of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on cardiac hypertrophy induced by chronic beta-adrenergic stimulation in rats
por: Miyoshi, Toru, et al.
Publicado: (2014)

Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double‐blind, randomized comparison of two uptitration regimens
por: Senni, Michele, et al.
Publicado: (2016)

LCZ696 mitigates diabetic-induced nephropathy through inhibiting oxidative stress, NF-κB mediated inflammation and glomerulosclerosis in rats
por: Mohany, Mohamed, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hda8jp90578roiivlm84fkh7ak